BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37120736)

  • 21. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
    Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
    Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
    Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
    Chotenimitkhun R; D'Agostino R; Lawrence JA; Hamilton CA; Jordan JH; Vasu S; Lash TL; Yeboah J; Herrington DM; Hundley WG
    Can J Cardiol; 2015 Mar; 31(3):302-7. PubMed ID: 25662284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
    D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
    Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials.
    Attar A; Behnagh AK; Hosseini M; Amanollahi F; Shafiekhani P; Kabir A
    Cardiovasc Ther; 2022; 2022():8367444. PubMed ID: 36687509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
    Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
    Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
    Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
    Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
    Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.
    Thavendiranathan P; Negishi T; Somerset E; Negishi K; Penicka M; Lemieux J; Aakhus S; Miyazaki S; Shirazi M; Galderisi M; Marwick TH;
    J Am Coll Cardiol; 2021 Feb; 77(4):392-401. PubMed ID: 33220426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
    Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
    ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
    Foulkes SJ; Howden EJ; Haykowsky MJ; Antill Y; Salim A; Nightingale SS; Loi S; Claus P; Janssens K; Mitchell AM; Wright L; Costello BT; Lindqvist A; Burnham L; Wallace I; Daly RM; Fraser SF; La Gerche A
    Circulation; 2023 Feb; 147(7):532-545. PubMed ID: 36342348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study.
    Liu J; Cao Y; Zhu K; Yao S; Yuan M; Kong X; Liu X; Li Y; Cui Y; Han X; Zhou X; Meng R; Shi H
    Quant Imaging Med Surg; 2022 Oct; 12(10):4771-4785. PubMed ID: 36185042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
    Cannata F; Stefanini G; Carlo-Stella C; Chiarito M; Figliozzi S; Novelli L; Lisi C; Bombace S; Panico C; Cosco F; Corrado F; Masci G; Mazza R; Ricci F; Monti L; Ferrante G; Santoro A; Francone M; da Costa BR; Jüni P; Condorelli G
    J Cardiovasc Med (Hagerstown); 2023 Jul; 24(7):469-474. PubMed ID: 37285278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.